News

In NHL, treatment with tazemetostat continues to demonstrate an encouraging profile with nine of 15 evaluable NHL patients achieving an objective response, including a partial response in the

The research collaboration will build on the company’s manufacturing protocol for its lead cancer program, CLBS20 (NBS20). All the parties will explore new techniques to further improve the

The Phase II Pathway Study’s primary efficacy outcome is the change in motor strength of the various muscle groups in the upper extremities innervated by the cervical spinal

The breakthrough therapy designation follows positive results from ARC001, which is the company’s randomized, double-blind, placebo-controlled Phase II trial of AR101 for desensitization treatment of peanut allergy. At

Glatopa is the first AP-rated substitutable generic designed to treat patients with relapsing-forms of multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation

The company said that the time frame for FDA review is about 30 days. CLI is caused by reduced blood flow to the legs and about half of

The trial is designed to assess the role of edoxaban in VTE patients associated with cancer (other than basal-cell or squamous-cell carcinoma of the skin) for whom long-term

In the clinical program, statistically significant differences in muscle strength as compared to a matched external control cohort and a favorable safety profile were observed. "We are excited

The Vectibix treatment arm further showed statistical significance for all key secondary endpoints including OS in patients with wild-type RAS (absence of mutations in exons 2, 3 and